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Abstract
Background: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve survival of rat-
to-mouse islet xenograft. The present study investigated the effect of combined RAPA/MR1 treatment on rat-to-mouse islet
xenograft survival and analyzed the role of CD4+CD25+Foxp3+ T regulatory cells (Treg) in the induction and maintenance of
the ensuing tolerance.
Methodology/Principal Findings: C57BL/6 mice were treated with MR1/RAPA and received additional monoclonal anti-IL2
mAb or anti CD25 mAb either early (0–28 d) or late (100–128 d) post-transplantation. Treg were characterised in the blood,
spleen, draining lymph nodes and within the graft of tolerant and rejecting mice by flow cytometry and
immunohistochemistry. Fourteen days of RAPA/MR1 combination therapy allowed indefinite islet graft survival in .80% of
the mice. Additional administration of anti-IL-2 mAb or depleting anti-CD25 mAb at the time of transplantation resulted in
rejection (100% and 89% respectively), whereas administration at 100 days post transplantation lead to lower rejection rates
(25% and 40% respectively). Tolerant mice showed an increase of Treg within the graft and in draining lymph nodes early post
transplantation, whereas 100 days post transplantation no significant increase of Treg was observed. Rejecting mice showed a
transient increase of Treg in the xenograft and secondary lymphoid organs, which disappeared within 7 days after rejection.
Conclusions/Significances: These results suggest a critical role for Treg in the induction phase of tolerance early after islet
xenotransplantation. These encouraging data support the need of developing further Treg therapy for overcoming the
species barrier in xenotransplantation.
Citation: Muller YD, Mai G, Morel P, Serre-Beinier V, Gonelle-Gispert C, et al. (2010) Anti-CD154 mAb and Rapamycin Induce T Regulatory Cell Mediated Tolerance
in Rat-to-Mouse Islet Transplantation. PLoS ONE 5(4): e10352. doi:10.1371/journal.pone.0010352
Editor: Derya Unutmaz, New York University, United States of America
Received February 3, 2010; Accepted March 31, 2010; Published April 26, 2010
Copyright:  2010 Muller et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Swiss National Research Fund grants # 3200BO-102134 (to P.M., D.B., T.B. and L.H.B.) and #3200B0-109921 (to J.D.S.), and
the Sir Jules Thorn Charitable Overseas Trust and Fondation Pierre Mercier Pour La Science. Novartis Pharma AG employed one of the authors of this study
(Christoph Heusser, PhD) and provided several monoclonal antibodies (anti-CD25 mAb, anti-IL2). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Novartis Pharma AG employed one of the authors of this study (Christoph Heusser, PhD) and provided several monoclonal antibodies
(anti-CD25 mAb, anti-IL2). However there are no patents/products in development/marketed productions in relation to this research. Indeed, another company
provides these antibodies. Thus this does not alter adherence to all the PLoS ONE policies on sharing data and materials, as detailed in the guide for authors.
* E-mail: leo.buhler@hcuge.ch
. These authors contributed equally to this work.
" These authors also contributed equally to this work.
Introduction
The inhibition of co-stimulation (signal 2) and proliferation
(signal 3) of T cell activation by co-stimulatory blockade and
rapamycin (RAPA) induces peripheral tolerance to allografts [1–3].
In contrast to central tolerance where self-antigen specific T cells are
depleted in the thymus, peripheral tolerance is achieved by various
mechanisms including: apoptosis of activated T cells, T cell anergy,
and active regulation by T regulatory cells (Treg) [4,5].
CD4+CD25+Foxp3+ T cells remain currently the best characterized
population of Treg in experimental transplantation (Tx) [6].
The variable role of Treg in the induction and maintenance of
allograft tolerance has been described in numerous models.
Induced Treg or ex-vivo generated antigen specific Treg have
been shown to protect allografts from immune-mediated damage
[7–9]. However, it is still poorly understood where and when
tolerization through Treg takes place [10]. Moreover their
potential role in xenogeneic models remains to be defined [11].
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We previously reported that treatment with anti-CD154 mAb
(MR1) significantly improved survival of rat islet xenograft in mice
[12,13]. Furthermore, RAPA has been shown to selectively
promote expansion of Treg in vitro and to prevent allograft
rejection in vivo. [14] [15,16]. The aim of the present study was to
investigate the effect of RAPA/MR1 combination therapy on
long-term xenograft acceptance and to further analyze the
mechanisms leading to tolerance, in particular the role of
regulation by CD4+ IL-2-dependent CD25+Foxp3+ Treg.
Materials and Methods
Animals
C57BL/6 mice between 6–10 weeks old were used as recipients
(Centre de Recherche et d’Elevage, Janvier, France). Adults
Sprague-Dawley rats, approximately 300–350 grams of body
weight, were used as islet donors (Janvier). Animals were maintained
in conventional housing facilities. Experiments involving animals
were performed in compliance with relevant laws according to
Geneva veterinary authorities and were approved by the ethical
committee of the Geneva University Medical School.
Islet isolation and xenotransplantation
Recipient mice were made diabetic by single intraperitoneal (i.p.)
injection of streptozotocin (Sigma, Buchs, Switzerland), 220 mg/kg
between 72–96 hours prior transplantation. Blood sugar levels were
monitored on regular intervals using a commercial kit (Precision
Q.I.D, MediSence, Abbott, Bedford, MA). Only mice with blood
sugar levels .17 mmol/L on two consecutive days were used for
Tx. Rat pancreatic islets were isolated as previously described [12].
Minimum 300 islet equivalent were transplanted per mice under the
left kidney capsule.
Experimental design
Anti-CD154 monoclonal antibody (mAb) (MR1, hamster anti-
mouse CD154 mAb (CD40L), Bio Express, West Lebanon, NH)
diluted in PBS (Sigma) was administered i.p. at 0.5 mg per mouse
on days 0, 2 and 4 post-Tx. The first dose, on day 0, was given
5 hours prior to Tx. Rapamycin (RAPA) (WYETH, Zug,
Switzerland) diluted in distilled water was administered by oral
gavage at 0.2 mg/kg on the first 3 days post-Tx, then every other
day up to day 14. Anti-IL-2 mAb (S4B6-1) and anti-CD25 mAb
(PC61), kind gifts from Novartis AG (Basel, Switzerland), were
diluted in PBS and administered i.p. 0.5 mg for the first injection,
then 0.3 mg twice weekly for four weeks respectively. Anti-IL-2
and anti-CD25 were started either at the time of Tx (early) or after
100 days (late). The following experimental groups were analyzed:
Group 1) Islet transplantation without further therapy (n = 34)
Group 2) RAPA therapy alone (n = 6)
Group 3) MR1 therapy alone (n = 9)
Group 4) Combination therapy RAPA/MR1 (n = 21)
Group 5) Combination therapy RAPA/MR1 with early anti-IL-
2 injection (n = 10)
Group 6) Combination therapy RAPA/MR1 with late anti-IL-2
injection (n = 4)
Group 7) Combination therapy RAPA/MR1 with early anti-
CD25 injection (n = 9)
Group 8) Combination therapy RAPA/MR1 with late anti-
CD25 injection (n = 7)
Graft survival follow-up
Islet graft function was determined by regular blood sugar
determination (Precision Q.I.D). Blood sugar levels of ,11 mmol
on two consecutive days defined successful islet function. Blood
sugar levels of .13 mmol on three consecutive days or a blood
sugar level of .17 mmol defined graft rejection.
Flow cytometry
CD4+CD25+Foxp3+ cells were considered as Treg and were
stained according to the manufacturer’s instructions (PE/APC
anti-Foxp3 (FJK-16s), FITC anti-CD4 (RM4–5), APC anti-CD25
(PC61.5), eBioscience, San Diego, CA). For Group 7 and 8,
animals receiving anti-CD25 mAb (PC 61.5), a non-crossreacting
clone of anti-CD25 mAb APC was used to detect Treg by FACS
(clone 3C7, Becton Dickinson, Franklin Lakes, NJ). Isotype control
antibodies were purchased from Becton Dickinson (FITC rat
IgG2a mAb, PE rat IgG2a, APC rat IgG1 mAb, APC rat IgG2b
mAb, APC rat IgG2a).
Levels of Treg were measured in blood on days 5, 10, 20, 50
and 100 in mice of Group 1, 4, 5, 7. Moreover, spleen and para-
aortic lymph nodes (paLN) were harvested for analysis of the
percentage and total numbers of Treg at various time points.
Group 1 animals were sacrificed either in the first 48 hours after
rejection, or between 48 hours and 7 days after rejection. In
Group 4, tolerant mice were sacrificed at days 20 and 100. Cell
counts were performed using Beckman coulter Z series (Hialeah,
FL). Flow cytometry acquisition was performed on FACScalibur
(Becton Dickinson) and data analyzed using Flowjo software (Tree
Star v. 8.7.3, Ashland, OR).
Histopathology and immunohistology
Nephrectomy (graftectomy) was performed either early after
rejection (,48 h) or between 48 h and 7days, or at day 20, 100 or
200 days post-islet Tx in tolerant recipients. Kidneys were either
preserved in formol 10% or frozen at 280uC.
Paraffin: kidney samples were fixed in formol 10%, then
embedded in paraffin and sectioned. Paraffin sections were used
for hematoxylin and eosin (HE). For insulin staining, sections were
incubated using guinea pig anti-porcine insulin antibody (DAKO
A564, Denmark) and subsequently with goat anti-guinea pig Alexa
488-conjugated (Invitrogen, Basel, Switzerland). Sections were
analyzed using a confocal microscope LSM510 meta (Zeiss
Axiophot, Go¨ttingen, Germany). For Foxp3 staining, sections
were baked at 55uC for 60 minutes, cooled, then deparaffinized
and rehydrated through graded alcohols to water. After antigen
retrieval in heated Tris-EDTA-Tween buffer, endogenous perox-
idase and biotin were blocked. The slides were then incubated
with biotinylated anti-Foxp3 (clone FJK-16s, eBioscience) followed
by Streptavidin/HRP (DAKO PO397) and liquid diaminobenzi-
dine-tetrahydrochloride plus substrate (DakoCytomation), rinsed
with water and counterstained with hematoxylin. Slides were
analyzed under an axiocam microscope (Zeiss).
Cryostat: kidney samples were stored at 280uC as previously
described [12]. Briefly serial frozen sections were stained for
characterization of infiltrating cells with anti CD4 mAb and anti-
CD8 mAb and anti mac-1 (Morphosys AbD Du¨sseldorf, Germany).
The slides were examined by fluorescence microscopy (Zeiss).
In vitro suppression assays
CD4+CD25+ Treg and CD4+CD252 T cells were isolated from
spleens of Group 1, Group 4 and naive mice by CD4 negative
selection followed by CD25 positive selection using a CD4+CD25+
regulatory T cell isolation kit (Miltenyi Biotec, Bergish Gladbach,
Germany). Treg and CD4+CD252 T cell purities were greater than
90%. A total of 56104 CD4+CD252 T cells isolated from naive
mice were co-cultured with 16105 irradiated (3500 Rad) syngeneic
splenocytes and anti-CD3e mAb (clone 145-2C11, eBioscience).
Treg of Group 1, Group 4 or naive mice were then added in
Tolerance and Islet
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triplicates at different ratios (506103, 256103, 12.56103 and
66103). Alternatively for the xenogeneic suppression assays, a total
of 0.46106 splenocytes isolated from naive mice were co-cultured
with 0.66106 irradiated (3500 Rad) xenogeneic third party Lewis or
donor Sprague Dawley splenocytes. 0.16106 Treg of Group 1,
Group 4 were then added in triplicates to the cultures. On day 5,
cells were pulsed with 1mCi3[H] of thymidine for 18 hours and then
harvested. Results are expressed as CPM showing one representa-
tive experiment. In the xenogeneic suppression assays results are
shown as the percentage of suppression and were calculated as:
100 * (CPM: naı¨ve splenocytes and xenogeneic stimulators) –
(CPM: naı¨ve splenocytes, xenogeneic stimulators and Treg)/
(CPM: naı¨ve splenocytes and xenogeneic stimulators)
One representative experiment is shown from at least two
separate experiments regrouping a total of 3 animals.
Quantitative RT-PCR
CD4+CD25+ T cells total RNA were harvested from the spleen
of rejector and tolerant recipient and prepared with Trizol. cDNA
was synthesized with random hexamers and Superscript II reverse
transcriptase (Invitrogen). PCR was performed with the iCycler iQ
Real-Time PCR Detection System and iQ SYBR green Supermix
(Bio-Rad).Results were quantified with a standard curve generated
with serial dilutions of a reference cDNA preparation. GAPDH
mRNA was used for normalization of Foxp3, IL-10 and
TGF-beta1 mRNA expression. Primer sequences are listed in
Table S1.
Statistical analysis
Prism software was used for statistical analysis (GraphPad
Software, San Diego California, USA). Survival curves were
calculated by the Kaplan and Meier method and analyzed using
Cox-Mantel test. MLR and in vitro suppression assays were
analyzed using one way ANOVA test; Bonferroni’s multiple
comparison method was used as post test. Non parametric Kruskal
Wallis test was used for analyzing the medians of Treg levels. A p-
value inferior to 0.05 was considered statistically significant.
Results
Islet graft survival
We first compared the effect of RAPA and MR1 on xenogeneic
islet graft survival, given alone or in combination, as summarized
in Figure 1A. Mice receiving no further therapy (n = 34) had a
median graft survival (MGS) of 13.5 days (Group 1). RAPA
therapy alone significantly prolonged rat islet survival to 24 days
(p,0.01), but all grafts were still rejected (Group 2). MR1 therapy
alone also significantly prolonged concordant islet xenograft
survival, in 5 of 9 mice (55.6%, p,0.0037) accepting their graft
over 100 days (Group 3). In Group 4, combination therapy with
MR1 and RAPA for 14 days resulted in graft survival for .100
days in 17/21 (80.9%, p,0.001) recipients.
We then investigated the mechanism underlining long-term
graft acceptance by administration of anti-IL-2 or anti-CD25 mAb
either at the time of Tx or 100 days post-Tx. In Group 5, early
administration of anti-IL-2 mAb also led to rejection in 10/10
mice (MGS 42 days). However, when anti-IL-2 mAb was given
100 days post-Tx, only 1 of 4 mice developed rejection at day 200
post-Tx (Group 6; Figure 1B). In Group 7, early administration of
anti-CD25 mAb, led to rejection in 8/9 mice (MGS 49 days).
However, when anti-CD25 mAb was given 100 days post-Tx, only
3 of 7 mice developed rejection at day 200 post-Tx (Group 8;
Figure 1C). Late tolerant mice (200 days post-Tx) were shown to
be hypo-responsive against donor antigen in contrast to rejecting
or naive recipient in mixed lymphocyte reaction (Figure S1,
Material and Methods S1).
Levels of Treg in blood, spleen and para-aortic lymph
nodes of tolerized mice vs rejecting mice
In order to understand the possible role of Treg in the acceptance
of islet xenograft their presence were investigated in the blood, lymph
nodes and spleen of tolerant and rejecting mice. The percentages of
CD25+Foxp3+ Treg within CD4+ T cells in 6 weeks old naive mice
were as previously described (Figure 2A–B, 2E) [9,17,18].
In Group 1, blood analysis of transplanted mice without further
therapy showed an increase of Treg from 9.8% at baseline to
16.4% at day 5 post-Tx and remained stable at day 20 post-Tx
(16.1%) (Figures 2D, 3A). Xenograft-rejecting mice were charac-
terized within the first 48 hours of rejection by a significant
increase of Treg percentages in the spleen from 9% at baseline to
13.7% (Figure 3B) and in paLN from 11.5% to 15.9% (Figure 3C).
Between 48 hours and 7 days after onset of rejection, the level of
Treg decreased again to 8.7% in the spleen (Figure 3B) and to
11.1% in paLN (Figure 3C). Absolute numbers of Treg varied
according to the percentage (data not shown). In summary,
rejecting mice showed an increase of Treg in secondary lymphoid
organs at the time of rejection, but after 48 hours to 7 days this
increase of Treg has faded away.
In Group 4, blood analysis of tolerant mice showed an increase
of the percentage of Treg from 9.8% at baseline to 14.8% at days
5 and to 12% 20 days post-Tx (Figure 3A). The percentage of
Treg in the spleen of tolerant mice was comparable to naive mice
of corresponding age (10.1% vs 9.1% at day 20, 11.4% vs 10.3%
at day 100, p.0.05 Figure 3B). In contrast, tolerant mice had
significantly higher levels of Treg in paLN at day 20 as compared
to naı¨ve mice (16.9% vs 11.5%, respectively p,0.01, Figure 3C).
After 100 days, no difference was detected in paLN between
tolerant mice and naive mice of corresponding age (15% vs 14.1%,
Figure 3C). Absolute numbers of Treg varied according to the
percentage (data not shown). Tolerant mice developed thus a
transient increase in the percentage and number of Treg in paLN
after tolerance induction 20 days post transplantation. This
difference was however not detectable any more at 100 days
when comparing tolerant to control naı¨ve mice.
In Group 5, blood analysis of transplanted mice receiving
RAPA/MR1 and early anti-IL-2, showed a decrease in Treg levels
to 5.4% at day 20 post-Tx (Figure 3A). Group 7, transplanted mice
receiving early anti-CD25, decreased Treg levels to 1.5% in blood
at day 20 post-Tx (Figures 2C, 2F, 3A). As previously reported,
both anti-CD25 mAb and anti-IL-2 mAb efficiently deplete Treg
in the peripheral blood.
The surgical procedure itself (sham transplantation), combined
with the injection of NaCl under the kidney capsule, had no effect
on Treg percentage in the blood (data not shown). The effect of
streptozotocin injected alone without further therapy was tested in
our model. Interestingly, this procedure increased Treg levels at
day 10 post-injection to 13.7% in blood, 13% in spleen and 17.7%
in paLN. Theoretically, this increase could be related to the
application of streptozotocin and/or the ensuing hyperglycemia.
Thus, the respective effect of streptozotocin and hyperglycemia on
Treg levels needs further investigation. All Groups of mice tended
to restore blood Treg levels over 50 days.
Histopathology and immunohistology of rat islet (graft)
in the mouse kidney (recipient)
The presence of Treg within the graft was analyzed by histology
and immunohistological staining as shown in Figure 4. In RAPA/
Tolerance and Islet
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Figure 1. Graft survival curves of the experimental Groups. A: Islet survival groups in mice receiving no additional therapy (Group 1),
rapamycin (RAPA) therapy alone (Group 2), anti-CD154 mAb (MR1) therapy alone (Group 3) and combination therapy of RAPA and MR1 (Group 4).
Tolerance and Islet
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MR1 treated tolerant mice (Group 4), Hematoxilin and eosin (HE)
analysis showed engraftment of islets under the kidney capsule at
day 20 post-transplant with minimal cellular infiltration within the
grafts (Figure 4A). Insulin staining confirmed well-preserved islets
(Figure 4B) and Foxp3 positive cells were present within the graft
(Figure 4C and D). After 100 days, islets of tolerant mice were still
preserved and HE analysis showed minimal cellular infiltration of
the grafts (Figure 4E), insulin staining confirmed the presence of
islets (Figure 4F) but Foxp3 positive cells were detected only at very
low frequency (Figure 4G–H).
In untreated mice (Group 1), HE analysis during early acute
rejection (,48 h) showed strong mononuclear cellular infiltration
(Figure 4I), insulin staining revealed islet disruption (Figure 4J) and
Foxp3 positive cells were present in the graft (Figure 4K–L). HE
staining of rejecting grafts between 48 hours and 7 days showed areas
of necrosis and tissue remodeling (Figure 4M). Only rarely islets cells
stained positive for insulin confirming the destruction of islets
(Figure 4N). There were few/no Foxp3 positive cells suggesting that
Treg disappeared after the destruction of the islets (Figure 4O–P).
Cryosection analysis of rejecting grafts was characterized by
cellular infiltration containing CD4+, CD8+ lymphocytes and
macrophages (Figure 5A–C). A humoral response was also
detected with IgG, IgM and C3 deposition (Figure S2). In
contrast, RAPA/MR1 treated mice showed minimal cellular
infiltration within the grafts 200 day post-Tx (Figure 5D–F) and
neither immunoglobulin (IgG and IgM) nor complement deposi-
tion was observed (Figure S2).
Treg of tolerant and rejecting recipients are both
suppressive
To assess the functionality of Treg from rejecting recipients,
tolerant mice, or naive mice, in vitro proliferation assays were
performed (Figure 6). Treg were isolated from the spleen of
untreated mice (Group 1) at day 10 before the occurrence of
Figure 2. Representative analysis of CD4+CD25+Foxp3+ cells in blood of C57BL/6 mice. Percentages of CD25+Foxp3+ Treg gated in CD4+ T
cell in the peripheral blood. Representative example of the gating in CD4+ T cells and the isotype controls used for CD25 (IgG1: pC61, IgG2b: 3C7) and
Foxp3 (IgG2a) are shown in the upper panel (A, B, C). Representative analysis of CD25+Foxp3+ Treg in Group 1, i.e. islet transplantation without
further therapy, at day 20 post-transplantation (D) in naive mice (E) and in Group 7, i.e early anti-CD25 mAb at day 20 post-transplantation (F).
doi:10.1371/journal.pone.0010352.g002
Effect of anti-IL-2 (B): Exogenous anti IL-2 mAb administration at the time of islet transplantation (Tx) (Group 5) or 100 days post Tx (Group 6) in
RAPA/MR1 treated mice. Effect of anti-CD25 (C): Exogenous anti CD25 mAb administration at the time of islet Tx (Group 7) or 100 days post Tx (Group
8) in RAPA/MR1 treated mice.
doi:10.1371/journal.pone.0010352.g001
Tolerance and Islet
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rejection and of Group 4 after tolerance induction at day 20. The
purity and mean fluorescence intensity of Foxp3+ cells gated in
CD4+CD25+ cells after isolation were comparable between the
groups (Figure 6A fluorescence intensity and 6B purity of Treg in
naive mice: 79.5%, in Group 1: 81.9% and in Group 4: 81.4%).
Treg of Group 1 and 4 both revealed suppressive activity
(Figure 6C). At a 1:1 ratio (or Treg to CD4+CD252 cells), Treg
completely inhibited the proliferation of co-cultured
CD4+CD252 cells in response to polyclonal stimulation (synge-
neic irradiated stimulators and anti-CD3 mAb). Interestingly
Treg of tolerant and rejecting animals showed no xenospecificity
in the in vitro xenogeneic suppression assays when compared
with donor Sprague Dawley or third party Lewis stimulators
(Figure 6D). In contrast, mRNA expression for Foxp3 was
increased in Treg of tolerant recipients but not in rejector
animals. TGF-b1 and IL-10 mRNA expression had a similar
trend (Figure 6E).
Discussion
Previous studies have demonstrated the induction of peripheral
tolerance to allogeneic antigens in small animal models by a
combined blockade of T cell costimulatory and proliferatory
signals [2,3]. In our model of islet xenotransplantation the
application of RAPA and MR1 for 14 days post Tx allowed
long-term survival of concordant islet xenografts over 100 days in
the majority of recipients. These results suggested that peripheral
tolerance was induced. However, as anti-CD154 mAbs are
unlikely to be introduced into the clinic due to thromboembolic
complications, the development of alternative strategies such as
anti-CD40 mAbs should be evaluated in future studies.
The combined blockade of the co-stimulation (signal 2) and
proliferation signaling (signal 3) with respectively MR1 and RAPA
showed a strong and potent tolerogenic effect in our model
(Figure 1). The ligation of CD40 by CD154 is crucial for activation
Figure 3. Flow cytometry analysis for Treg level in blood, spleen and para-aortic lymph nodes. A: Blood Treg levels over time in Group 1
(transplanted mice without further therapy), Group 4 (RAPA/MR1 treated mice), Group 5 (RAPA/MR1 treated mice and early administration of anti IL-2
mAb), and Group 7 (RAPA/MR1 treated mice and early administration of anti CD25 mAb). Treg levels in spleen (B) and para-aortic lymph nodes (C). In
Group 1, mice were analyzed ,48 hours of rejection and between .48 hours and 7 days of rejection. In Group 4 Treg levels were analyzed 20 days
post transplantation. All results were calculated with median and range. Kruksal-Wallis test and Dunn’s Multiple Comparison post Test was used. *
P,0.05, ** P,0.01 and ***P,0.001 were considered significant.
doi:10.1371/journal.pone.0010352.g003
Tolerance and Islet
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and maturation of dendritic cells though upregulation of MHC
and the costimulatory molecules CD80 and CD86, for activation
and class switch of B cells and for the production of pro-
inflammatory molecules such as TNF and IL-12 [19]. T cell
activation is further inhibited through the anti-proliferative effect
of RAPA. In addition, RAPA and MR1 have been described
respectively to promote expansion of Treg and to enhance their
levels of suppressive activities [20–23]. Consequently, the Treg
suppressive activity may have potentiated the simultaneous
blockade of signal 2 (co-stimulation) and signal 3 (proliferation)
allowing development of long term graft tolerance. Therefore, the
potential role of Treg in tolerance induction and maintenance was
further investigated. In line with the concept of IL-2 dependency
of Treg [24,25], we used anti-IL-2 mAb (S4B6-1) and anti-CD25
mAb (PC61) to ‘‘starve’’ or to deplete Treg consistent with other
reports using the same clones [26–28]. Administration of anti-IL-2
Figure 4. Immuno-histology of grafts in tolerant vs rejecting recipients. Graft staining of Group 4 (tolerant mice) at day 20 post-transplant
(A–D), graft staining of Group 4 (tolerant mice) at day 100 post-transplant (E–H), graft staining of Group 1 (rejecting mice) within the first 48 hours of
rejection (I–L) and graft staining of Group 1 (rejecting mice) between 48 hours and 7 days of rejection (M–P). A, E, I, M, Hematoxylin & eosin
(magnification 200x), B, F, J, N Insulin immunofluorescence (green, magnification 200x), Foxp3 immunochemistry (brawn intranuclear staining) C, D,
G, K Magnification 200x and D, H, L, P Magnification 600x.
doi:10.1371/journal.pone.0010352.g004
Tolerance and Islet
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or anti-CD25 mAb at the time of islet Tx efficiently depleted Treg
in the peripheral blood (Figure 2F, 3A) and was associated with a
90–100% rejection rate in MR1 and RAPA treated recipients.
However, when these reagents were given 100 days post-Tx in
tolerant animals, significantly less mice developed late rejection.
This result suggests that Treg are essential during the induction
phase of tolerance, i.e. immediately following concordant islet
xenotransplantation under RAPA and MR1. Intriguingly, during
the maintenance phase of tolerance, rejection is triggered by anti-
IL2/anti-CD25 in some mice, suggesting a variable role for
regulation at late time points post-transplant. This observation
may be explained by a progressive decline in the role of Treg as
deletion progresses over time. A similar process has been observed
in other tolerance models [29]. Such a scenario is further
supported by the increase in Treg numbers in the early phase
post-transplant, but not in the late phase (Figure 3). Thus there will
be a prolonged period during which both deletion and regulation
are important. Depending on the specific degree of its contribution
in individual mice at any given time, it would be expected that
abrogation of regulation may lead to rejection or not.
The balance between effector T cells and Treg depends on the
local microenvironment which seems to be an essential factor
determining the fate of a graft [30]. No correlation was found
between the percentage of Treg in blood and the fate of the
xenograft. Indeed rejecting and tolerant mice had both higher
percentages of Treg in the blood compared to baseline. In rejecting
mice, Treg transiently increased in every compartment including
the secondary lymphoid organs and the graft early during rejection
(,48 h). A few days post-rejection, Treg disappeared in all
compartments highlighting the importance of the time course post
transplantation when Treg are analyzed. Contradictory studies
have reported either an increase or a decrease of Treg in rejecting
recipients [31–33]. Haanstra et al. transplanted allogeneic non-
human primate kidneys and performed serial biopsies of these grafts
over time showing infiltration of Treg in rejecting grafts. Wang et al.
transplanted allogeneic mouse kidneys and found a reduction of
Foxp3 expression in graft of rejecting mice. It is likely that these
contradicting results can be due to different timing in assessment of
Treg during the rejection process. In our study, suppression assays
confirmed the functionality of Treg in rejecting recipient which was
similar to Treg of tolerant mice. These results suggest that functional
Treg develop during the process of rejection in response to
xenoantigens, and that these cells disappear after the destruction
of the islet xenograft.
Figure 5. Cellular infiltration in rejecting and tolerant grafts. Cryostat sections were stained by anti-mouse CD4 (A–D), CD8 (B–D) and
macrophage antibodies (C–E) in Group 1 (A–B–C) and Group 4 at 200 days post transplantation. In Group 1 of rejecting mice, immunohistology for
cellular immune responses to concordant islet xenografts at time of rejection has detected mixed cellular infiltrates with presence of CD4+ (A), CD8+
(B), and macrophages (C). In Group 4 of tolerant mice, immunohistology for cellular immune responses to concordant islet xenografts of tolerant
mice at 200 days post-transplantation detected only minimal cellular infiltrate with absence of CD4+ (D), CD8+ (E), and macrophages (F).
(Magnification in A–C (200x), Magnification in D–F(100x)).
doi:10.1371/journal.pone.0010352.g005
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In tolerant mice, Treg depletion early post-Tx resulted in
rejection. These findings correlated with higher frequencies of
Treg in the grafts and paLN at day 20 post-Tx, when compared to
day 100 post Tx, which is consistent with the notion of draining
lymph nodes and the graft itself as being primary sites for Treg
function [9,34–37]. Furthermore, the lack of an increase of Treg in
the spleen is in line with other (allo-)tolerance models [38].
However, due to a lack of available markers the respective roles of
induced and natural Treg in the early phase towards tolerance
induction could not be examined. Thus, because induced and
natural Treg may play different roles through different mecha-
nisms during tolerance induction, it will be of interest to
understand whether the observed increase of Treg in the draining
lymph nodes and within the graft is the consequence of migrating
natural Treg or of a local conversion of naive T cells to induced
regulators. In our xenotransplantation model, Treg harvested
from the spleen of tolerant animals expressed higher mRNA levels
of Foxp3 suggesting a higher functional status, as reported recently
[39]. However when tested in vitro, Treg of tolerant mice were
neither more suppressive than Treg of rejector mice, nor
xenospecific except when third party stimulators were used. These
findings may be explained by the low frequency of donor specific-
Treg induced in the spleen, despite the fact that RAPA/MR1
treatment has a non-specific systemic effect on Treg as shown by
the increased levels of Foxp3. In summary, these results emphasize
the importance of the compartmentalization of the xenogeneic
immune response and its regulation.
In conclusion, administration of anti-IL-2 mAb or anti-CD25
mAb during the time of Tx prevented tolerance induction in our
islet xenotransplantation model, suggesting that regulation by IL-
2-dependent CD4+CD25+ T regulatory cells was critical in the
induction of tolerance during the immediate post-Tx period.
Delayed administration of anti-IL-2 mAb or anti-CD25 mAb did
not abrogate tolerance in most recipients, indicating that
maintenance of tolerance became less dependent on regulation
over time, possibly indicating a role of progressive clonal deletion.
These results were confirmed by the presence of Treg in paLN and
grafts of tolerant mice early post-Tx but not after 100 days post-Tx
Figure 6. Functional characterization of Treg in rejecting and tolerant mice. Treg were isolated form the spleen of Group 1 (rejecting mice)
at day 10 post transplantation before rejection occurrence and of Group 4 (tolerant mice) at day 20 after tolerance induction. Three mice per Group in
3 separate experiments showed similar mean fluorescence intensity (A) and purity (B) of Foxp3+ cells (gated on CD4+CD25+). Treg of Group 1 and 4
were used at different ratio (1:1, 1:2, 1:4, and 1:8) in co-culture with syngeneic responders (CD4+CD25+) and stimulators and anti CD3e mAb (C). Treg
xenospecificity was assed by co-culture of naive mice splenocytes with donor Sprague Dawley or third party Lewis stimulators plus minus rejector or
tolerant Treg. Percentage of suppression are shown (D). Foxp3, TGFb-1 and IL-10 mRNA expression were measured by real time PCR. Results were
calculated on basis of relative mRNA expression compared to naive mice (relative expression = 1, E).
doi:10.1371/journal.pone.0010352.g006
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suggesting a critical role of Treg for xenograft acceptance early
after concordant islet xenotransplantation.
Supporting Information
Table S1 Primer sequences used for real time PCR are listed in
Table S1.
Found at: doi:10.1371/journal.pone.0010352.s001 (0.03 MB
DOC)
Material and Methods S1
Found at: doi:10.1371/journal.pone.0010352.s002 (0.03 MB
DOC)
Figure S1 Concordant xeno- and allo-responses are diminished in late
tolerant mice. White bars, naı¨ve mice; gray bars: Group 6, (late anti-
IL2 treatment); black bars: Group 8 (late anti-CD25 mAb
treatment). Alternatively Sprague donor strain splenocytes, Lewis
splenocytes, BALB/c splenocytes or human PBMC were used as
stimulators. In late anti-IL2 mAb and late anti-CD25 mAb
treatment groups, graft-tolerant mice demonstrated MLR re-
sponses against donor cells that were reduced approximately 60%
compared to control group and maintained a robust T cell
proliferation against human stimulator cells. Surprisingly, graft-
tolerant mice also showed significantly decreased T cell prolifer-
ation indices against allogeneic (Balb mouse) and xenogeneic
(Lewis rat) stimulators compared to naı¨ve mice. In rejecting mice,
all mean stimulation indices were not statistically different when
compared to naı¨ve mice (data not shown). Late tolerant mice (200
days post tx) were shown to be hypo-responsive against donor
antigen in contrast to rejecting or naive recipient in mixed
lymphocyte reaction. Stimulation index was calculated as CPM of
responder lymphocytes stimulated by allo- or xenogeneic stimu-
lators divided by CPM of responder lymphocytes stimulated by self
stimulators. All results were calculated with mean and standard
deviation. One way ANOVA test and Bonferroni’s multiple
comparison post test was used. * P,0.05, ** P,0.01 and
***P,0.001 were considered significant.
Found at: doi:10.1371/journal.pone.0010352.s003 (4.77 MB TIF)
Figure S2 Humoral response and complement deposition analysis of
rejecting and tolerant mice. Immunohistology for humoral immune
responses to concordant islet xenografts in untreated C57BL/6
mice and in combination therapy (MR1+RAPA) treated mice at
200 days post transplantation. Sections were stained by anti-mouse
IgG (A/D), IgM (B/E) and complement (C3, C/F). A humoral
response was detected at rejection with the presence of IgG (A),
IgM (B), and C3 (C), whereas neither immunoglobulin (IgG, D,
and IgM, E,) nor complement deposition (F) was observed in
tolerant grafts. (Magnification IgG (100x), IgM (100x), C3 (100x)).
Found at: doi:10.1371/journal.pone.0010352.s004 (6.70 MB TIF)
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